论文信息 - A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours - 字舞流文

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

J. Schellens | M. D. de Jonge | M. Langenberg | M. Lolkema | S. Goodstal | A. Varga | K. Hsu | S. Macé | G. Tuffal | B. Demers | K. Thomas | V. D. de Weger | E. Deutsch